Functionally selective D1 agonists that have less β-arrestin activity may have less side effects in Parkinson’s disease because ERK1/2 activation correlated with levodopa-induced dyskinesia, whereas blocking ERK1/2 activation significantly decreased it [30]. The gene discussed is MAPK3; the disease is Parkinson disease.